EDRH
SGMO

Edmond de Rothschild Holding’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Edmond de Rothschild Holding’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,500
Closed -$4.4K – 751
2023
Q1 		$4.4K Hold
2,500
– – ﹤0.01% 706
2022
Q4 		$7.85K Hold
2,500
– – ﹤0.01% 750
2022
Q3 		$12K Hold
2,500
– – ﹤0.01% 765
2022
Q2 		$10K Buy
+2,500
New +$10.8K ﹤0.01% 759

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edmond de Rothschild Holding's SGMO Position: Q2 2023 in Review

Edmond de Rothschild Holding sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 2,500 shares — an estimated $4.4K sold.

Edmond de Rothschild Holding first reported a position in SGMO in Q2 2022 and held it in 4 quarters. The position peaked at $12K in Q3 2022. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Edmond de Rothschild Holding reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Edmond de Rothschild Holding sold 2,500 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $4.4K.
  • Edmond de Rothschild Holding first reported a position in SANGAMO THERAPEUTICS INC in Q2 2022 and held it in 4 quarters.
  • Edmond de Rothschild Holding's SANGAMO THERAPEUTICS INC position peaked at $12K in Q3 2022.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Edmond de Rothschild Holding's 13F filing for Q2 2023, filed 9 Aug 2023.